Despite these advancements, the application of PD-1/PD-L1 inhibitors in CRC faces significant challenges, particularly in tumors with pMMR or MSS phenotypes, a group which constitutes the majority of CRC cases. Here, PDCD1 is linked to colorectal carcinoma.